Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217203 · ClinicalTrials.gov registry record · Phase 1
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
A Phase 1 study, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01217203 is a Phase 1 study that has completed, run by Innate Pharma. The registered enrollment target is 15 participants.
The verdict
NCT01217203, a Phase 1 study, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
Interventions
- DRUG IPH2101 combined to lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217203
The ClinicalTrials.gov registry entry for NCT01217203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPH2101 combined to lenalidomide is the first listed.
NCT01217203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01217203 about?
NCT01217203 is a clinical study titled "Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse". The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
What is the current status of trial NCT01217203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01217203?
The interventions under investigation include: IPH2101 combined to lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01217203?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.